U.S. – Page 2 – Talk Bio

Johnson & Johnson Commits $2B to Fujifilm North Carolina Site in Latest US Manufacturing Push

2 months ago talkbio0Tagged Billion, Biopharma, Fujifilm, Investments, Johnson and Johnson, Manufacturing, North Carolina, Surgical construction, U.S.

Johnson & Johnson; Fujifilm; manufacturing; North Carolina; $2 billion investment; biopharma; job creation; US manufacturing

GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal

3 months ago talkbio0Tagged BioNTech, BioNTech acquisition, COVID19 (disease), CureVac, global framework, Influenza virus vaccine, Licensing, Litigation, Pfizer, RNA, Messenger, royalties, settlement, SmithKline Beecham, U.S., upfront payment, Vaccines, Vaccines, Combined

GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac

Amid MFN Talks, Lilly Chief Warns US Adoption of International Drug Prices Could Bring ‘Worst of Two Worlds’

3 months ago talkbio0Tagged Cautionary Warning, Chief, Does speak, Drug Industry, drug price, Eli Lilly, International Drug Prices, MFN, Policy, U.S.

Lilly chief; MFN talks; international drug prices; US drug pricing; pharmaceutical industry; policy warning

Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

3 months ago talkbio0Tagged 15%, European (ethnic group), Evaluation, pharmaceutical tariffs, Sectioning technique, tariff, trade agreement, Transplant Registry Unified Management Program, U.S., Union, US-EU

Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement

Adaptimmune Expects To Cut 62% of Staff After Cell Therapy Asset Sale

3 months ago talkbio0Tagged Adaptimmune, Afami-cel, biotech workforce, cell therapy sale, layoffs, restructuring, Tecelra, U.S., WorldMeds

Adaptimmune; layoffs; cell therapy sale; US WorldMeds; restructuring; biotech workforce reduction; TECELRA; lete-cel; afami-cel; uza-cel

Trump Threatens 200% Tariffs on Pharma Imports, Proposes 1-Year Grace Period for Onshoring

4 months ago talkbio0Tagged 200, Biopharma, drug imports, grace, Investments, Menstruation, onshoring, Pharma, pharmaceutical tariffs, Policy, tariff, Transplant Registry Unified Management Program, U.S.

Trump; pharmaceutical tariffs; 200% tariff; grace period; pharma manufacturing; drug imports; US supply chain; onshoring; policy; biopharma investments

UCB Announces Major Investment to Expand US Biologics Manufacturing Capacity

4 months ago talkbio0Tagged Biological Factors, biomanufacturing, economic impact, expansion, Investments, Manufacturing, U.S., UCB

UCB; biologics manufacturing; US expansion; biomanufacturing; biopharmaceutical; investment; jobs; economic impact

Sanofi Opens $130M ‘Flagship’ US Office Facility in Morristown, New Jersey

5 months ago talkbio0Tagged Corporate, flagship office, Health care facility, innovation, Market, Morristown, sanofi, U.S.

Sanofi; Morristown; flagship office; $130 million; healthcare; innovation; New Jersey; US market; corporate hub

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

5 months ago talkbio0Tagged Biological Science Disciplines, Biopharma, biopharma survey, biotech careers, Drug Industry, employment, Industry, Market, Transition Mutation, trends qualifier, U.S.

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry

Pharma Companies Eye ‘First Sale’ Rule to Lessen Tariff Costs Amid New US Trade Measures

5 months ago talkbio0Tagged customs loophole, drug import duties, Drug Industry, first, minimis exemption, sale rule, tariff avoidance, trade compliance, Trump administration, U.S., US tariffs

first sale rule; pharmaceutical industry; US tariffs; customs loophole; drug import duties; tariff avoidance; trade compliance; Trump administration; de minimis exemption